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In a new report, Nyati et al. identified a previously undetected participant mediating both canonical signaling, i.e.,
TGF-β receptor kinase mediated, and non-canonical signaling, budding uninhibited by benzimidazole 1 (BUB1).
Neoplasia (2015) 17, 153–154Despite more than a quarter century and a vast literature, understanding
transforming growth factor–β (TGFβ) signaling continues to be a major
research enterprise because TGFβ is a central hub in both homeostasis and
disease. TheTGFβ1 isoform is the foundingmember of a superfamily that
orchestrates cell interactions, regulates phenotype, and acts as a critical
switch inmany key tissue repair processes. In a new report, Nyati et al. has
identified a previously undetected participant mediating both canonical,
i.e., TGFβ receptor kinasemediated, andnon-canonical signaling [1]. This
group conducted a small interfering RNA (siRNA) screen of the human
kinome using a live-cell reporter for TGFβ receptor (TGFBR) activity in
two cancer lines. The screen successfully identified many proteins with
known roles, and the authors chose to characterize budding uninhibited by
benzimidazole 1 (BUB1) as a target using a high stringency strategy for
selection. BUB1was validated in sixmalignant and non-malignant human
cell lines from various tissues in which siRNA activity abrogated the
activation of SMAD2 and SMAD3 as well as components of the
non-canonical signaling cascade (c-JUN, p38 mitogen-activated protein
kinase, and AKT). Although BUB1 knockdown in one cell line, A549,
also decreased TGFBR type I (TGFBRI), this was not necessary in othercell lines nor did BUB1 siRNA mimic TGFBRI small molecule inhibitor
effects, confirming it as an independent mediator of TGFβ signaling.
BUB1 depletion abrogated the formation of the TGFBRI–TGFBR
type II (TGFBRII) complex. The authors showed that BUB1
promotes the TGFBRI-TGFBRII complex formation, in which
BUB1 interacts with both TGFBRI and TGFBRII, but does not
require TGFBR1 kinase activity. However, BUB1 kinase activity is
necessary for TGFβ canonical signaling even though BUB1 does not
directly phosphorylate TGFBRI or phosphorylate purified SMAD3
in vitro. Importantly, BUB1 kinase activity is also important for
non-canonical signaling through Akt and p38 mitogen-activated
protein kinase. The authors conclude that BUB1 forms a ternary
complex with the ligand and both receptors; signaling requires
BUB1's Ser/Thr kinase activity, but the actual BUB1 substrate
required for TGFβ signaling is as yet unknown.
Thus, BUB1 joins the ongoing delineation of TGFβ signaling in a
complex network that controls its actions across cell types, but this
new member is particularly intriguing in regards to cancer. The
TGFβ switch from tumor suppressor to tumor promoter remains one
of the major hallmarks of epithelial cancers, whose normal
counterparts are profoundly growth inhibited by femtomolar
TGFβ concentrations. BUB1 is a mitotic checkpoint protein that
also has a role in regulating kinetochore-microtubule attachments
(reviewed in [2]). Notably, its deletion rapidly leads to aneuploidy,
which is a relatively underappreciated consequence of TGFβ1
knockout [3,4].
Nyati et al. have uncovered a pathway interaction that has far-reaching
implications in understanding the loss of genomic stability in cancer and
may have therapeutic applications as well. Intriguingly, there is growing
evidence that TGFβ is necessary for genomic stability and pluripotency in
stem cells and DNA damage response in differentiated cells. In one study
of five human embryonic stem cell lines, BUB1 is among the 1% of genes
expressed across all lines in the undifferentiated states, and clustered with
previously reported stemness genes responsible for self-renewal and
pluripotent differentiation, concurrent with highly expressed TGFβ
154 Barcellos-Hoff Commentarysignaling components, TGFBRI and SMAD2 [5].Of particular interest is
that either BUB1 [6] or TGFβ1 deletion [7] impairs DNA damage
recognition and increases sensitivity to ionizing radiation. This is one
example of many neoplastic processes in which TGFβ is implicated, and
underscores how the addition of BUB1 as a necessary component of
TGFβ signaling has the potential to clarify the aspects of TGFβ
phenotypes that have long puzzled the community.References
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